Masimo Corporation (MASI)
After hours:
| Previous close | 117.13 |
| Open | 117.39 |
| Bid | 117.45 x 200 |
| Ask | 117.59 x 100 |
| Day's range | 117.15 - 118.54 |
| 52-week range | 75.22 - 153.93 |
| Volume | |
| Avg. volume | 708,360 |
| Market cap | 6.253B |
| Beta (5Y monthly) | 0.97 |
| PE ratio (TTM) | 79.95 |
| EPS (TTM) | 1.47 |
| Earnings date | 05 Nov 2024 - 11 Nov 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 23 Nov 2012 |
| 1y target est | 155.00 |
- Business Wire
Masimo to Present in Wells Fargo Healthcare Conference
IRVINE, Calif., August 29, 2024--Masimo (NASDAQ: MASI) today announced that its management will participate in the Wells Fargo Healthcare Conference on Thursday, September 5, 2024 at 10:15 a.m. Eastern Time. A live webcast of the presentation will be available on the Masimo website at www.masimo.com. A replay of the webcast will be available following the live presentation.
Business WireMasimo Partners with March of Dimes to Help Parents with Babies in the NICU Make the Transition from Hospital to Home
IRVINE, Calif., August 27, 2024--Masimo (NASDAQ: MASI), a global leader in innovative monitoring technologies used in top hospitals, and March of Dimes, the leading non-profit organization fighting to improve health outcomes for all moms and babies, are launching a partnership to support new parents with babies in the Neonatal Intensive Care Unit (NICU). Between 9 to 13 percent of babies born require a stay in the NICU due to complex medical needs1, and many babies born preterm, with birth defec
Business WireMasimo Has the Right Leadership and Strategy to Drive Long-Term Value Creation
IRVINE, Calif., August 26, 2024--Masimo Corporation ("Masimo" or the "Company") (NASDAQ: MASI), a global leader in noninvasive monitoring technologies and audio products, today mailed a letter to stockholders in connection with its upcoming Annual Meeting of Stockholders (the "Annual Meeting") to be held on September 19, 2024, highlighting the Company’s commitment to long-term value creation and the risks to its continued momentum and innovation if Politan were to gain control of the Company’s B
